TICKERNERD
Menu
IMRXIMRXHealthcare · Biotechnology

IMRX Stock Forecast: Immuneering Corp. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$5.18
−2.26% on the day

The 8 Wall Street analysts covering Immuneering Corp. hold a median 12-month price target of $17 — +228.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$342.9M
Ticker Nerd rank
46 / 100
Median analyst target
$17
Analysts covering
8
Total return, dividends reinvested
1W
−0.8%
1M
+19.9%
YTD
−21.3%
1Y
+5.9%
From 52W high
−44.1%
From 52W low
+32.1%
$3.92
$9.26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immuneering Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
67
Growth
66
Momentum
64
Size
60
Value
53
Revisions
49
Issuance
34
Volatility
25
Accruals
25

Quality (67): The business earns solid, repeatable profits on what it owns.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26IMRXHigh $30Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $12Median $17High $30

The green dot is the last close — the median target sits +228.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026HC Wainwright & Co.InitiatesBuy$14
20 July 2026NeedhamMaintainsBuy$11 → $18
20 July 2026NeedhamMaintainsBuy—
8 July 2026Cantor FitzgeraldInitiatesOverweight—
8 July 2026Cantor FitzgeraldInitiatesOverweight—
19 May 2026Chardan CapitalMaintainsBuy—
9 Mar 2026NeedhamReiteratesBuy—
13 Nov 2025Chardan CapitalMaintainsBuy—
31 Oct 2025Leerink PartnersInitiatesOutperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
26 Sept 2025Chardan CapitalMaintainsBuy—
25 Sept 2025OppenheimerMaintainsOutperform—
15 Sept 2025NeedhamMaintainsBuy—
26 Aug 2025NeedhamReiteratesBuy—
14 Aug 2025Chardan CapitalMaintainsBuy—
18 June 2025Chardan CapitalMaintainsBuy—
18 June 2025MizuhoMaintainsOutperform—
18 June 2025NeedhamReiteratesBuy—
5 June 2025NeedhamReiteratesBuy—
7 May 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IMRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Immuneering Corp. (IMRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
1.8×

Cheaper than 51% of US stocks

EV / EBITDA
−3.1×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.1%

Higher than 21% of US stocks

Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMRXImmuneering Corp.$342.9M
46
SABSSAB Biotherapeutics, Inc.$343.9M
36
STROSutro Biopharma, Inc.$344.8M
75
ABEOAbeona Therapeutics, Inc.$347.4M
42
IKTInhibikase Therapeutics, Inc.$333.5M
31
DMACDiaMedica Therapeutics, Inc.$351.6M
48
YDESYD Bio Ltd.$330.7M
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immuneering Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMRX news & analysis

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 5 Aug 2026positive

Immuneering Corp. reported second quarter 2026 financial results and business updates. Highlights include a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, an ongoing Phase 3 MAPKeeper 301 trial with patients dosed across over 30 sites, a peer-reviewed Cancer Research publication on atebimetinib preclinical activity, and $182.7 million in cash with anticipated runway into 2029.

Why it matters — The reported survival data, ongoing Phase 3 program, and funding runway are key clinical and financial milestones for IMRX's lead candidate atebimetinib.

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'

Seeking Alpha · 27 July 2026positive

Immuneering Corporation's atebimetinib showed promising Phase 2a results in first-line pancreatic cancer, with a pivotal Phase 3 trial now recruiting and first patient dosing expected by mid-2026. The company's cash runway is projected into 2029.

Why it matters — An IMRX watcher would care because atebimetinib's median overall survival of 17.3 months outperformed historical controls and compared favorably to competitors' data, suggesting the drug could be a significant treatment option in first-line pancreatic cancer.

FAQ

Frequently asked questions about IMRX stock

What is the IMRX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Immuneering Corp. have a median 12-month price target of $17, with estimates ranging from $12 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMRX stock a buy right now?

Of the 8 analysts covering Immuneering Corp., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immuneering Corp. 46 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMRX?

As at 22 Aug 2026, Immuneering Corp. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (67 of 100).

Will IMRX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +228.2% from the last close, and Ticker Nerd's factor model ranks Immuneering Corp. 46 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMRX stock forecast for 2030?

No analyst covering Immuneering Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $30 over the next 12 months.

How has IMRX stock performed over the past year?

Immuneering Corp. returned +5.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immuneering Corp. do?

Immuneering Corporation is a clinical-stage biotechnology company focused on developing oncology therapies for patients with cancers driven by dysregulated cell-signaling pathways. The company is headquartered in Cambridge, Massachusetts, and concentrates its research on a proprietary class of small-molecule drugs known as Deep Cyclic Inhibitors.

What is the latest news on IMRX?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates". Immuneering Corp. reported second quarter 2026 financial results and business updates. Highlights include a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, an ongoing Phase 3 MAPKeeper 301 trial with patients dosed across over 30 sites, a peer-reviewed Cancer Research publication on atebimetinib preclinical activity, and $182.7 million in cash with anticipated runway into 2029.

Company

About Immuneering Corp.

Immuneering Corporation is a clinical-stage biotechnology company focused on developing oncology therapies for patients with cancers driven by dysregulated cell-signaling pathways. The company is headquartered in Cambridge, Massachusetts, and concentrates its research on a proprietary class of small-molecule drugs known as Deep Cyclic Inhibitors. These medicines are designed to selectively and intermittently target components of the MAPK signaling pathway, with the aim of limiting tumor adaptation while maintaining tolerability for patients. Immuneering Corporation’s lead programs target MAPK pathway-driven tumors, including difficult-to-treat solid cancers such as pancreatic cancer. Its experimental therapies are being evaluated as monotherapies and in combination with standard chemotherapies in multiple clinical studies. By focusing on mechanism-based design and precision targeting of oncogenic signaling, Immuneering Corporation plays a specialized role in the oncology drug development landscape, working with clinicians and research centers to advance potential new treatment options for patients with advanced malignancies.

CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D. · 57 employees · United States · https://immuneering.com